Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Core Insights - Zymeworks Inc. is focused on advancing its pipeline of multifunctional biotherapeutics aimed at treating difficult diseases, including cancer and autoimmune conditions, with strategic priorities set for 2025 and 2026 [1][2] Key 2024 Accomplishments - The company achieved its first FDA approval for zanidatamab and made significant clinical progress with antibody-based therapeutics in solid tumors [2] - Zymeworks has a strong financial position with approximately $324 million in cash and marketable securities as of December 31, 2024, which supports operations into the second half of 2027 [4][9] - The company initiated first-in-human studies for ZW171 and ZW191, and plans to submit IND applications for ZW220 and ZW251 in 2025 [5][11] 2025 and 2026 Priorities - Zymeworks aims to continue the clinical development of its solid tumor pipeline and expand its R&D efforts into autoimmune and inflammatory diseases [7][11] - The company expects to present at the J.P. Morgan Annual Healthcare Conference on January 16, 2024, to discuss its strategic priorities [10] Regulatory and Clinical Milestones - Top-line results for the Phase 3 HERIZON-GEA-01 trial for Ziihera® (zanidatamab-hrii) are anticipated in Q2 2025, with potential regulatory submissions in the EU and China for zanidatamab in second-line biliary tract cancer expected as early as Q2 2025 [4][12] - The company is advancing its proprietary platforms to enhance product innovation and diversify its pipeline [11][12]